Sarah Moats
Endocrinology, Diabetes & Metabolism · Reno, NVNPI 1457703985
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Kyowa Kirin, Inc. at 31.2% of the total. 2025 is the largest year on record at $11,126, 6.4 times the $1,732 reported in 2023.
Across 302 payments — averaging $75.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kyowa Kirin, Inc.$7K
- AstraZeneca$7K
- Amgen$1K
- Corcept Therapeutics$843
- Lilly USA, LLC$825
- Xeris Pharmaceuticals, Inc.$687
- plus $6K from 29 others
What the payments were for
- Consulting fees$10,59046%
- Travel & lodging$2,0589%
- Food & beverage$10,16145%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kyowa Kirin, Inc. | 15 | $7,106 |
| AstraZeneca(2 entities) | 21 | $6,544 |
| Amgen(2 entities) | 28 | $1,193 |
| Corcept Therapeutics | 21 | $843 |
| Lilly USA, LLC | 26 | $825 |
| Xeris Pharmaceuticals, Inc. | 27 | $687 |
| Medtronic | 23 | $653 |
| Novo Nordisk | 18 | $602 |
| Ascendis Pharma Endocrinology Inc | 8 | $494 |
| Sanofi-aventis U.S. LLC | 12 | $470 |
| Recordati_rare_diseases_inc. | 13 | $429 |
| Mannkind Corporation | 17 | $408 |
| Boehringer Ingelheim | 10 | $322 |
| Bayer | 9 | $316 |
| Neurocrine Biosciences, Inc. | 4 | $249 |
| Chiesi USA, Inc. | 6 | $234 |
| Ascensia Diabetes Care US Inc. | 3 | $177 |
| Insulet Corporation | 4 | $176 |
| Lexicon Pharmaceuticals, Inc. | 2 | $173 |
| Antares Pharma, Inc. | 7 | $165 |
| AbbVie | 7 | $135 |
| Soleno Therapeutics, Inc. | 1 | $119 |
| Almatica Pharma LLC | 5 | $117 |
| Astellas Pharma US Inc | 3 | $77 |
| Madrigal Pharmaceuticals | 1 | $41 |
| Radius Health, Inc. | 2 | $35 |
| Sequel Med Tech, LLC | 1 | $35 |
| Rhythm Pharmaceuticals, Inc. | 1 | $33 |
| Alvogen Inc | 1 | $26 |
| Verity Pharmaceuticals Inc. | 1 | $25 |
| Amryt Pharma Holdings Ltd | 1 | $24 |
| Tandem Diabetes Care, Inc. | 1 | $23 |
| Pfizer | 1 | $18 |
| IBSA Pharma Inc. | 1 | $18 |
| Averitas Pharma Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,809 in reported general payments places this provider in the 80th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
See all endocrinology, diabetes & metabolism providers in Nevada →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 26 | $38,001 |
| MounjaroTirzepatide | 21 | $33,554 |
| JardianceEmpagliflozin | 26 | $28,943 |
| TrulicityDulaglutide | 21 | $22,030 |
| SynthroidLevothyroxine Sodium | 97 | $10,021 |
| Levothyroxine Sodium | 153 | $1,580 |
| Liothyronine Sodium | 33 | $1,450 |
| LevoxylLevothyroxine Sodium | 34 | $1,260 |
| Hydrocortisone | 12 | $781 |
| Atorvastatin Calcium | 14 | $319 |
| Methimazole | 30 | $275 |
| Metformin Hcl | 11 | $108 |
| Rosuvastatin Calcium | 17 | $98 |
| Metformin Hcl ErMetformin Hcl | 14 | $86 |
| Glipizide | 11 | $70 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $825 | $55,58442 claims |
| Novo NordiskOzempic | $602 | $38,00126 claims |
| Boehringer IngelheimJardiance | $322 | $28,94326 claims |
| AbbVieSynthroid | $135 | $10,02197 claims |
| PfizerLevoxyl | $18 | $1,26034 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
Other endocrinology, diabetes & metabolism in Reno
- Nitesh KuhadiyaReno$595K
- Lisa AbbottReno$130K
- Michael Raymund GonzalesReno$90K
- Claude LardinoisReno$65K
- Daniel CarusoReno$12K
- Robert FredericksReno$10K
- Polina ZykovaReno$7K
- David HowardReno$2K
- James AtchesonReno$2K
- Fadi HendeeReno$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.